Last reviewed · How we verify
DLX105 Hydrogel
DLX105 Hydrogel is a Local anesthetic Small molecule drug developed by Delenex Therapeutics AG. It is currently in Phase 2 development for Postoperative pain management.
DLX105 Hydrogel is a hydrogel formulation of a local anesthetic.
DLX105 Hydrogel is a small molecule intervention being studied for the treatment of Psoriasis Vulgaris in a Phase II clinical trial. It is a topical hydrogel formulation, likely containing hypochlorous acid, which is being compared to a placebo in a double-blind, randomized study.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DLX105 Hydrogel |
|---|---|
| Sponsor | Delenex Therapeutics AG |
| Drug class | Local anesthetic |
| Target | Sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 2 |
Mechanism of action
DLX105 Hydrogel works by releasing a local anesthetic to provide pain relief. The exact mechanism of action is not well understood, but it is thought to involve the inhibition of sodium channels in nerve cells, preventing the transmission of pain signals.
Approved indications
- Postoperative pain management
Common side effects
- Numbness
- Tingling
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DLX105 Hydrogel CI brief — competitive landscape report
- DLX105 Hydrogel updates RSS · CI watch RSS
- Delenex Therapeutics AG portfolio CI
Frequently asked questions about DLX105 Hydrogel
What is DLX105 Hydrogel?
How does DLX105 Hydrogel work?
What is DLX105 Hydrogel used for?
Who makes DLX105 Hydrogel?
What drug class is DLX105 Hydrogel in?
What development phase is DLX105 Hydrogel in?
What are the side effects of DLX105 Hydrogel?
What does DLX105 Hydrogel target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Sodium channels
- Manufacturer: Delenex Therapeutics AG — full pipeline
- Therapeutic area: All drugs in Pain management
- Indication: Drugs for Postoperative pain management
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing